Business Wire

Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...

Tracking health across a lifetime: Northern Finland Birth Cohort 1966 launches new follow-up as participants turn 60

One of the world's most extensive birth cohorts is now entering later adulthood. At the University of Oulu in Finland, the ...
European Medical Journal

MDMA-Assisted Therapy Shows Sustained Benefits in Depression

MDMA-assisted therapy may provide lasting benefit for patients with MDD. Seven-month follow-up shows sustained symptom ...
Nasdaq

Biofrontera says last patient completed one-year follow-up in Ameluz-PDT study

Biofrontera announced that a key milestone in its Phase 3 study of the use of Ameluz and RhodoLED PDT in the treatment of sBCC was met with the last patient completing the 1 year follow-up visit in ...
The American Journal of Managed Care

Timely Outpatient Follow-Up Reduces Hospital Readmissions

Adequate outpatient follow-up within 30 days significantly reduces 30-day all-cause hospital readmissions, impacting hospital finances and patient care quality. The study analyzed 83 studies, ...
Business Wire

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today ...